Form 4: Werewolf Therapeutics Director Michael Atkins Granted 27,000 Stock Options

Werewolf Therapeutics, Inc. director Michael B. Atkins was granted 27,000 stock options with an exercise price of $1.29, vesting over one year or until the next annual meeting.

Summary

• Michael B. Atkins, a Director of Werewolf Therapeutics, Inc. (HOWL), was granted 27,000 stock options on June 12, 2025.
• The stock options have an exercise price of $1.29 per share.
• These options are set to vest in full on the earlier of June 12, 2026 (the first anniversary of the grant date) or the next annual meeting of stockholders, contingent upon Mr. Atkins' continued service as a director.
• The options have an expiration date of June 11, 2035.
• Following this transaction, Mr. Atkins beneficially owns 27,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning management interests with shareholders but does not provide new operational or financial performance insights.

Positives

• The grant of stock options aligns Director Michael B. Atkins' interests with the long-term performance and shareholder value creation of Werewolf Therapeutics, Inc.
• This represents a standard form of equity compensation, incentivizing continued service and commitment from a key board member.

Negatives

• No specific negative information is contained within this Form 4 filing, as it primarily reports a routine equity grant.

Risks

• This Form 4 filing, being a report of an insider transaction, does not detail specific company risks. Risks related to the company's operations, financial health, or market conditions would typically be found in other SEC filings like 10-K or 10-Q.

Future Outlook

The vesting schedule of the granted stock options, contingent on continued service, indicates an expectation for Director Michael B. Atkins to remain on the board for at least one more year or until the next annual meeting, aligning his future interests with the company's performance.

Management Comments

• This Form 4 filing does not contain direct quotes or paraphrased statements from company management, as it is a transactional report.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, serving as a key component of executive and director compensation packages. This practice aims to align the interests of board members with those of shareholders by tying a portion of their compensation to the company's stock performance.

Comparison to Industry Standards

• The grant of 27,000 stock options to a director with a vesting period tied to continued service is a standard form of equity compensation.
• While the specific number and exercise price are unique to Werewolf Therapeutics and its compensation philosophy, the mechanism itself is consistent with compensation practices observed in comparable small to mid-cap biotechnology companies.
• Without specific compensation benchmarks for similar roles at companies like Moderna (MRNA), BioNTech (BNTX), or other emerging biotech firms, a direct quantitative comparison of the grant size is difficult, but the structure is typical.

Related Party Transactions

• The grant of stock options to Director Michael B. Atkins constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The equity grant aims to align the director's financial interests with shareholder value creation, potentially leading to more shareholder-friendly decisions.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Management: The grant reinforces the compensation structure for the board, potentially influencing retention and motivation of key personnel.

Next Steps

• The granted stock options will vest in full on the earlier of June 12, 2026, or the next annual meeting of stockholders, subject to continued service.
• Director Michael B. Atkins may exercise these options at any time after vesting and before the expiration date of June 11, 2035.

Key Dates

Keywords

Werewolf Therapeutics, HOWL, Stock Option Grant, Director Compensation, Insider Transaction, SEC Form 4, Equity Incentive, Beneficial Ownership